The reduction of drug reimbursement levels in France means that consumers are literally confronted with the price, according to Jacques Vilain, director of TEV Consultants, which, with the pharmacy journal Le Moniteur, found this to be one of the major trends in a survey they undertook of pharmacy consumers.
The poll concluded that it is now "inconceivable" for a French consumer to buy a drug product without being aware of its price. It also found a number of evolving trends, with consumers seeking more autonomy and the choice between several alternative products, although 71% of those polled remained generally satisfied with the user information provided.
Dissatisfaction focused on the lack of sufficient information on prices. mr Vilain said it had been made clear that it was up to pharmacists to convince customers through "advice and competence" that the price was fair. Also, customers wanted to be able to consult information about prospective drug purchases on the spot.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze